Quick Read – LLY raised 2026 guidance to $82B-$85B as Mounjaro and Zepbound surged, while NVO guided to an adjusted sales decline and cut 9,000 jobs. – Novo pre-announced 50% Wegovy and 35% Ozempic price cuts effective January 2027, capping future cash flow but protecting volume…
NVO trades at a P/E near 12. – Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Eli Lilly didn’t make the cut. Grab the names FREE today
Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) both posted Q1 FY2026 results this spring, and the gap between them keeps widening. Lilly delivered 55.55% revenue growth and raised guidance. Novo, meanwhile, is quietly restructuring after guiding to an adjusted sales decline of -4% to -12% at constant currency.
Same drug class, very different quarters. Foundayo Sprints. Wegovy Pill Defends.